Revenue segments as reported by the company.

Premium and service revenues

Premium tax

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Depreciation

Amortization of acquired intangible assets

Premium tax expense

Health insurer fee expense

Impairment

Legal settlement

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Centene

Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid. The Specialty Services segment offers healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company was founded in 1984 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Centene exceeds earnings guidance, eyes growth in Marketplace products

Centene's Q4 2022 earnings call highlighted robust financial performance, successful execution of value-creation plans, and a focus on operational efficiency. While challenges in Medicare Advantage margins are anticipated, opportunities in the Marketplace business and cost-cutting initiatives offer avenues for growth. Strategic initiatives to address demographic shifts and enhance care relationships position Centene for future success.

Centene reports strong Q1 earnings, focuses on growth opportunities

Centene's Q1 performance reflects strength in financial results and a strategic outlook for future growth.
Despite challenges in Medicare profitability and Medicaid redeterminations, Centene remains focused on maximizing membership and maintaining high margins.
Opportunities in enhancing relationships, investing in infrastructure, and updating margin assumptions position Centene for long-term success.

Centene reports strong Q2 earnings, raises 2023 outlook amidst challenges

Centene's Q2 earnings call showcased robust financial performance, operational efficiencies, and strategic wins in Medicaid and Marketplace segments. While facing challenges in cost trends and Star ratings strategy, the company is well-positioned for growth through revenue expansion and value-creation initiatives. Opportunities for engagement with key stakeholders and successful outreach efforts present avenues for continued success.

Centene exceeds Q3 earnings expectations, eyes growth opportunities in 2024

Centene's Q3 2023 earnings call highlighted strong financial performance, progress in Medicaid redeterminations, and operational advancements. The company anticipates continued growth in adjusted EPS for 2023 and 2024, with a focus on margin expansion and operational efficiencies. Challenges include managing membership declines and addressing questions on business plans and cost implications.

Centene exceeds 2023 expectations, poised for growth in 2024

Centene's 2023 performance was strong, exceeding expectations and positioning the company for continued growth. Key initiatives in Medicaid, Medicare Advantage, and Marketplace are driving revenue growth and operational efficiency. Challenges in managing utilization trends and achieving target margins require ongoing attention.

Centene surpasses Q1 earnings expectations, eyes growth in Medicaid and Marketplace

Centene's Q1 performance exceeded expectations, showcasing strength in Medicaid and Marketplace segments.
While facing challenges in contract protests and operational clarity, the company's strategic focus on Medicare Advantage and growth opportunities remain key strengths.
With a robust financial outlook and ongoing initiatives for optimization, Centene is well-positioned for continued success in the healthcare market.
Investors can be optimistic about Centene's growth trajectory, supported by strong operational performance and strategic initiatives.

Centene reports robust Q2 earnings, eyes Medicaid rebound and Medicare growth

Centene's Q2 2024 earnings call highlighted strong performance, Medicaid challenges, and growth opportunities in Medicaid and Medicare markets. Leadership transitions and focus on program innovation are key areas of development for the company.

Centene surpasses Q3 earnings expectations, eyes growth amid challenges

Centene's Q3 performance exceeded expectations, driven by improvements in Medicaid and strong Medicare and Marketplace segments.
Despite challenges in Medicaid and competitive pressures, Centene remains confident in its future growth and operational enhancements.
The company's strategic focus on AI, margin expansion, and quality improvement positions it well for continued success and profitability.
Analyst inquiries and company responses highlighted key areas of focus and potential areas for improvement and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, international operations, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

We think that Centene stock (NYSE: CNC) currently is a better pick compared to the pharmaceuticals bellwether Johnson & Johnson stock (NYSE: JNJ), given Centene's better prospects and comparatively lower valuation.

Here's Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether

Creating Human Connections, Meeting Patients Where They Are, and Keeping Solutions Simple among Key Best Practices to Improving Access and Driving Health Equity SACRAMENTO, Calif., May 12, 2022 /PRNewswire/ -- Health Net, one of California's longest serving and most experienced Medi-Cal partners, today released new research outlining best practices for expanding access to care as well as reducing health disparities among some of the state's most vulnerable residents.

California's Most Vulnerable Get Boost in Access to Health Care by Data Driven Human Outreach and Relentless Drive for Simplicity, Report Finds

LOS ANGELES & ST. LOUIS--(BUSINESS WIRE)--Behavioral Health Center of Excellence (BHCOE), a data-driven healthcare accreditor, today announced a strategic partnership with Centene Corporation (NYSE:CNC) that will research and advance continuous improvement in Applied Behavioral Analysis (ABA) treatment delivery and support access to quality services for people on the autism spectrum and related developmental disabilities. This partnership brings together BHCOE's quality measurement expertise as

Behavioral Health Center of Excellence and Centene Announce Partnership to Advance Quality in Autism Treatment Outcomes

ST. LOUIS , May 6, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its Missouri subsidiary, Home State Health, has been awarded the MO HealthNet Managed Care General Plan and Specialty Plan. Under the General Plan, Home State will continue serving multiple MO HealthNet programs including Children's Health Insurance (CHIP) members and the state's newly implemented Medicaid expansion population, across all regions of Missouri.

Centene Subsidiary Selected to Continue Serving Missouri's Medicaid Managed Care Members and Wins Single Source Foster Care Specialty Contract

Centene saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 93 the day before. The post Stocks With Rising Composite Ratings: Centene appeared first on Investor's Business Daily.

Stocks With Rising Composite Ratings: Centene

Investor consortium plans to partner with PANTHERx Rare to fuel its continued expansion as a leading rare and orphan focused specialty pharmacy PITTSBURGH, NEW YORK, PROVIDENCE, R.I. and CHICAGO, May 5, 2022 /PRNewswire/ -- A leading investor consortium consisting of Nautic Partners, The Vistria Group and General Atlantic today announced it has signed a definitive agreement to acquire PANTHERx Rare ("PANTHERx" or "The Company") from Centene Corporation (NYSE: CNC).

General Atlantic, Nautic Partners and The Vistria Group Announce Strategic Acquisition of PANTHERx Rare From Centene Corporation

Microsoft

PepsiCo

Macroeconomic factors have challenged a lot of companies lately -- but these three companies have succeeded anyway.

3 Growth Stocks That Beat Earnings Despite Inflation

~ Centene to sell Magellan Rx to Prime Therapeutics ~ ~ Centene to sell PANTHERx to The Vistria Group, General Atlantic, and Nautic Partners ~ ~ Centene expects to receive aggregate proceeds of approximately $2.8 billion ~ ~ Two significant milestones in value creation program and ongoing portfolio review ~ ST. LOUIS , May 5, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has signed a definitive agreement to sell Magellan Rx to Prime Therapeutics LLC (Prime) and a separate definitive agreement to sell PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.

CENTENE SIGNS DEFINITIVE AGREEMENTS TO DIVEST TWO PHARMACY BUSINESSES IN SEPARATE TRANSACTIONS

ST. LOUIS , May 3, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today it will present at the Bank of America 2022 Healthcare Conference, to be held Monday, May 9-Friday, May 13, 2022, in Las Vegas. Centene will present on Tuesday, May 10 th at 8:40 a.m.

CENTENE TO PRESENT AT BANK OF AMERICA 2022 HEALTHCARE CONFERENCE

Centene reported Q122 earnings this week and beat street estimates with EPS of $1.83, whilst also raising guidance slightly. The company lost its long-term CEO Michael Niedorff earlier this year. The CEO passed away at the age of 79.

Centene: Solid Q122 Earnings For Health Insurer Helps Make Buy/Hold Case

Ryder System

U.S. Silica Holdings

Exxon Mobil

The earnings season is coming in soft as expected, but there should be a boost from energy stocks later this week.

Buy XOM, SLCA, CNC and R Before Earnings Reports?

Centene Corporation (NYSE:CNC ) Q1 2022 Results Conference Call April 26, 2022 8:30 AM ET Company Participants Jennifer Gilligan - VP, IR Sarah London - CEO Drew Asher - EVP, CFO Brent Layton - President, COO Kevin Counihan - SVP, Products Conference Call Participants Justin Lake - Wolfe Research Joshua Raskin - Nephron Research Scott Fidel - Stephens Matt Borsch - BMO Capital Markets Adam Ron - Bank of America Gary Taylor - Cowen Nathan Rich - Goldman Sachs A.J. Rice - Credit Suisse Michael Ha - Morgan Stanley George Hill - Deutsche Bank Steven Valiquette - Barclays Calvin Sternick - JPMorgan Benjamin Flox - Jefferies Operator Good day, and welcome to the Centene Corporation First Quarter 2022 Earnings Results Conference Call.

Centene Corporation (CNC) CEO Sarah London on Q1 2022 Results - Earnings Call Transcript

Centene's (CNC) first-quarter results highlight improved premium and service revenues and, higher membership growth. An increased 2022 guidance with respect to EPS and revenues should impress investors.

Centene (CNC) Q1 Earnings Beat Estimates, Ups '22 EPS View

Centene (CNC) delivered earnings and revenue surprises of 8.93% and 7.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Centene (CNC) Q1 Earnings and Revenues Surpass Estimates

Centene Corp. CNC, +0.53% reported Tuesday first-quarter profit and revenue that rose above expectations, amid strength in its Medicare and Medicaid businesses, and raised its full-year earnings outlook. The health care services company's stock was still inactive in premarket trading.

Centene profit and revenue rise above expectations, full-year outlook lifted

-- Diluted EPS of $1.44; Adjusted Diluted EPS of $1.83 -- -- Raises Total Revenue and Adjusted EPS Guidance -- ST. LOUIS , April 26, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its financial results for the first quarter ended March 31, 2022, reporting diluted earnings per share (EPS) of $1.44 and adjusted diluted EPS of $1.83.

CENTENE CORPORATION REPORTS FIRST QUARTER 2022 RESULTS AND INCREASES 2022 GUIDANCE

Centene's (CNC) first-quarter results are likely to reflect growing revenues attributable to a rise in premiums and membership, partly offset by lower investment income.

What to Expect From Centene (CNC) this Earnings Season?

DETROIT , April 21, 2022 /PRNewswire/ -- In today's world of technology, many youth experience the negative consequences of increased connectivity and socialization in the form of cyberbullying. Cyberbullying differs from traditional bullying in several ways, and as a result, Meridian wants to educate adults and youth across Michigan about the risks of cyberbullying and how it impacts overall health.

Meridian Shines a Light on Cyberbullying and Encourages Michigan Youth to Make a Difference

ST. LOUIS , April 15, 2022 /PRNewswire/ -- Centene Corporation's (NYSE: CNC) Board of Directors issued the following statement today: The Centene Board has accepted the resignation of Leslie V. Norwalk, Esq.

CENTENE BOARD ISSUES STATEMENT ON DEPARTURE OF BOARD MEMBER

Neidorff built Centene through Medicaid contracts and strict cost controls. His successor is under pressure to increase margins.

What Centene's Next Era in Managed Care Looks Like

DETROIT , April 4, 2022 /PRNewswire/ -- Meridian Michigan, a provider of government-sponsored health plans, announced today that it has appointed Dr. Kay Judge as its new Chief Medical Officer, effective April 10, 2022.  Dr. Judge brings over two decades of experience from large health systems in Michigan and California.

Meridian Michigan Announces Appointment of New Chief Medical Officer

– Live Audio Webcast of Annual Meeting Available – ST. LOUIS , April 1, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that following the release of its 2022 first quarter financial results on Tuesday, April 26, 2022, the Company will hold its 2022 Annual Meeting of Stockholders at 11:00 a.m.

CENTENE TO HOLD 2022 ANNUAL MEETING FOLLOWING 2022 FIRST QUARTER FINANCIAL RESULTS CONFERENCE CALL

Centene Corp   (NYSE:CNC) stock is down 0.4% to trade $85.29 at last check, just one week removed from a March 21, record high of $88.61.

Why This Healthcare Stock's Pullback May Be Short-Lived

NEW YORK, March 23, 2022 /PRNewswire/ -- Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that Jesse Hunter will join the Firm as an Operating Partner in its Healthcare Group. Mr. Hunter is an accomplished executive with extensive experience driving growth and creating value across the healthcare ecosystem.

Jesse Hunter Joins Welsh, Carson, Anderson & Stowe as Healthcare Operating Partner

ST. LOUIS, March 22, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that Sarah London, Vice Chairman of Centene, has been appointed Chief Executive Officer, effective immediately, succeeding Michael Neidorff. Mr. Neidorff remains on a previously announced medical leave of absence from his position on the Board of the Company.

News for Centene Stock (CNC)